The DNA damage response helps to maintain genome integrity, suppress tumorigenesis, and mediate the effects of radiotherapy and chemotherapy. Our previous studies have shown that Smad1 is upregulated and activated by Atm in DNA damage response, which can further bind to p53 and promote p53 stabilization. Here we report another aspect of the interplay between p53 and Smad1. Comparison of rectal tumor against paired paraneoplastic specimens and analysis of >500 colorectal tumors revealed that Smad1 was upregulated in tumor samples, which was attributable to p53 defects. Using MEFs as a model, we found that knockdown of the elevated Smad1 in p53 2/2 MEFs promoted cell proliferation, E1A/Ras-induced cell transformation, and tumorigenesis. Mechanistic studies suggest that elevated Smad1 and momentary activation inhibit cell proliferation by upregulating p57Kip2 and enhancing Atm -Chk2 activation. Surprisingly, elevated Smad1 appears to have a negative effect on chemotherapy, as colorectal tumors, primary cancer cells, and cell lines with Smad1 knockdown all showed an increase in chemosensitivity, which could be attributable to elevated p57Kip2. These findings underscore the significance of Smad1-p53 interaction in tumor suppression and reveal an unexpected role for Smad1 in chemoresistance of colorectal cancers.
Introduction
Tumor suppressor p53 is regarded as the guardian of the genome. Activation of p53 by genotoxic stress or oncogene activation turns on its target genes such as p21, Puma, and Bax to induce cell cycle arrest, apoptosis, and/or senescence, thus maintaining genome integrity and suppressing tumorigenesis caused by accumulation of mutations in oncogenes and tumor suppressor genes (Jackson and Bartek, 2009; Lord and Ashworth, 2012; Reinhardt and Schumacher, 2012) . As such, p53 gene is mutated in .50% of the primary tumors, which express mutant p53 molecules that either lose the normal function or display dominant-negative effects (Vogelstein et al., 2000; Goh et al., 2011; Muller and Vousden, 2013) . The lack of p53 function automatically leads to escape of cell senescence and immortalization and promotes cell transformation. In addition, p53 deficiency has been shown to affect cell differentiation in several cell types, including neuron and osteoblast (Ma et al., 2012; Liu et al., 2013) , although the mechanisms by which p53 regulates cell differentiation remain under-explored.
Due to its critical roles in cell proliferation, differentiation, and death, the p53 expression needs to be tightly regulated. A Mdm2-p53 loop provides such a mechanism for fine-tuning p53 expression (Brooks and Gu, 2006) . Moreover, the levels of p53 are also influenced by the energy level, nutrition, and other growth conditions of the cell, in addition to the severity of DNA damage. For example, it has been shown that growth factorsactivated mTOR-S6K1 pathway has an influence on p53 induction in response to DNA damage (Lai et al., 2010) . In addition, p53 deficiency leads to positive feedback regulation of the expression of genes that have redundant function as p53, e.g. p16INK4a and p73 (Kravchenko et al., 2008; Leong et al., 2009; Lunghi et al., 2009; Hong et al., 2014) . It is understandable that an important protein such as p53 needs to be tightly regulated and when mutated, compensatory mechanisms need to kick in.
Our previous studies showed that Samd1 is upregulated and further activated in response to DNA damage. DNA lesions especially double-stranded DNA breaks activate the Atm -p53 and Atm -Chk2 pathways to induce cell cycle arrest and apoptosis (Jackson and Bartek, 2009) . DNA damage-induced Smad1 activation requires Atm and Atm-mediated phosphorylation of Smad1 on Ser239, which also promotes Smad1-p53 interaction and inhibits Mdm2-mediated p53 ubiquitination, leading to p53 upregulation (Chau et al., 2012) . This provides a mechanistic explanation how BMP-Smad1 signaling suppresses tumor development (Howe et al., 2001; Hardwick et al., 2008; Thawani et al., 2010; Walsh et al., 2010; Tomlinson et al., 2011; Gao et al., 2012; Lubbe et al., 2012) . In this study, we uncovered a novel aspect of the functional interaction between p53 and Smad1. We found that Smad1 is upregulated in human colorectal tumor specimens compared with normal tissues or paired paraneoplastic samples, which is attributable to p53 deficiency. This elevation helps to curb cell proliferation, cell transformation, and tumor formation, by increasing the expression of cyclin-dependent kinase inhibitor p57Kip2, a Smad1 target gene (Jia et al., 2014) , and potentiating Atm -Chk2 activation. In addition, elevated Smad1 appears to render chemoresistance in tumor models and human rectal cancer cells, which could be explained by increased p57Kip2 expression. These findings suggest that Smad1 elevation serves as a compensatory mechanism for p53 deficiency by potentiating the activation of p53 parallel pathways, and that Smad1 plays critical roles not only in tumor suppression but also in chemosensitivity. In addition, parallel studies show that the functions of Smad1 in tumor suppression and chemosensitivity are not shared by Smad5.
Results

Rectal tumor samples show Smad1 upregulation compared with paraneoplastic tissues
Our previous studies have shown that Atm-mediated Smad1 Ser239 phosphorylation promotes Smad1 upregulation and activation and leads to p53 stabilization. To test the clinical relevance of this finding, we collected 22 rectal tumors (5 stage I samples, 6 stage II samples, 8 stage III samples, and 3 stage IV samples; for patient information, see Supplementary Table S1, sample 9 being discarded due to protein degradation) and paraneoplastic specimens and analyzed Smad1 expression. We found that both protein ( Figure 1A and B) and mRNA ( Figure 1C and D) levels of Smad1 were significantly upregulated in the tumor samples compared with matched paraneoplastic samples. However, the protein levels of Smad4, an important tumor suppressor (Derynck et al., 2001) , and Smad5 were not significantly altered (Supplementary Figure S1) . Surprisingly, we found that Smad1/ 5/8 activation was reduced in most of the tumor samples even in the presence of elevated Smad1 expression ( Figure 1A ). This is consistent with previous findings that Smad1/5/8 activation is inhibited in colorectal tumor samples due to mutations in bone morphogenetic protein (BMP) receptors (Sancho et al., 2004; Kodach et al., 2008) , and suggests that BMP-Smad1 signaling plays complex roles in tumor development and progression.
Smad1 upregulation is common in human colorectal cancer samples
To validate the finding of Smad1 upregulation in tumors, we collected 542 human colorectal tumor specimens (stages I to IV) and 53 normal tissues, which were obtained from Chinese Han population (for patient information, see Supplementary Table S2 ). These tissues were used to generate tissue arrays, which were immunohistochemically stained for Smad1, and the levels of Smad1 were scored (Supplementary Figure S2A) . We found that Smad1 was expressed at low levels in normal mucosa samples, yet tumor patient samples expressed increased levels of Smad1 (from 17% to 64%) ( Table 1) . At later stages, Smad1 levels appeared to go down. In the tumor samples with increased Smad1 expression, immunohistochemical staining showed that Smad1 was detectable in both the cytoplasm and the nucleus, just like in normal tissues (Supplementary Figure S2B) . These results indicate that colorectal tumors tend to upregulate Smad1 expression. The function of Smad1 upregulation is the focus of present study.
Smad1 upregulation is attributable to p53 defects
Previous studies have shown that primary p53 2/2 osteoblasts and neural stem cells (NSCs) displayed elevated Smad1 expression, which have an impact on osteogenic and neural differentiation, respectively (Ma et al., 2012; Liu et al., 2013) . To determine whether Smad1 upregulation is related to p53 in tumor samples, we analyzed the protein levels of p53 in 22 pairs of samples by western blot and found that p53 was either downregulated or expressed in truncated forms in .70% tumor samples ( Figure 1A ). Sequencing the p53 cDNA obtained from 22 samples confirmed the existence of various p53 mutations (Supplementary Table S1 ). Five of the tumor samples carry R175H mutations, and two carry G245R mutation. Moreover, 16 of them carry P72R, a common polymorphism of p53 gene that is associated with tumorigenesis (Aaltonen et al., 2001; Olivier et al., 2010) , two of which also carry R248W and R282W mutations. Some of the tumors that do not carry mutations showed a decrease in p53 protein level. These results suggest that p53 defects are common in colorectal cancers.
Comparison of p53 down-regulation/mutations with Smad1 upregulation revealed that there exists a significant correlation between p53 defects and Smad1 upregulation (Figure 2A) , suggesting that p53 suppresses the expression of Smad1 in human colorectal tumors. We then isolated primary rectal cancer cells from three patient samples, which showed a great reduction in p53 and an elevation in Smad1 compared with its paired paraneoplastic sample ( Figure 2B and Supplementary Figure S3A) . The sample shown in Figure 2B carries a R175H mutation in p53 gene. To test whether the increase in Smad1 is a result of p53 deficiency, we ectopically expressed p53 using a retroviral vector in the tumor cells and found that p53, but not p53-R273H mutant, reduced the protein level of Smad1 ( Figure 2C and D, and Supplementary Figure S3B ). These results, taken together, suggest that p53 defects contribute to Smad1 elevation.
Knockdown of Smad1 promotes proliferation of p53
2/2 MEFs p53 mutation is a frequent and early event in some tumor types (Rivlin et al., 2011; Vinall et al., 2012) . Our previous studies showed that p53 is often mutated during MEF immortalization, a process that is required for cell transformation (Zhang et al., 2013a) . We used primary MEFs to test the function of Smad1 elevation in relation to p53 deficiency. We found that primary p53 2/2 MEFs showed elevated levels of Smad1 but not Samd5 ( Figure 3A) . It has been shown that p53 deficiency induced Smad1 upregulation in osteoblasts and NSCs during differentiation via E2F1 (Ma et al., 2012) . To confirm that p53 represses Smad1 expression under normal growth conditions via the same mechanisms, we knocked down E2F1 with siRNA in p53 2/2 MEFs, which also led to a decrease in Smad1 ( Figure 3A) . Importantly, Smad1 elevation is accompanied by an increase in Smad1/5/8 activation in p53
MEFs. The findings that primary MEFs, osteoblasts, and NSCs show co-elevation of Smad1 expression and Smad1/5/8 activation in response to p53 deficiency suggest that p53 defects initially lead to elevated Smad1 expression and activation, which is later deactivated due to alteration in upstream regulators of BMP-Smad1 signaling during tumorigenesis.
To test the function of Smad1 upregulation in p53 2/2 cells, we knocked down Smad1 in p53 2/2 MEFs using short hairpin RNA (shRNA) expressed by a retroviral vector, with WT MEFs as a control ( Figure 3B) . Four shRNA hairpins were tested and two of them (37928 and 30824) produced similar degrees of Smad1 knockdown as siRNA ( Figure 3B and Supplementary Figure S4 ), and thus were used further in this study. We found that p53
MEFs with Smad1 knockdown showed enhanced proliferation ( Figure 3C ), evidenced by an increase in the number of cells after the same number of cells were plated. Similar results were obtained from Smad1-knockdown WT MEFs ( Figure 3C ). In addition, analysis of the cell cycle profiles revealed that Smad1 knockdown led to an increase in S phase especially in p53
2/2 cells ( Figure 3D ). These findings suggest that Smad1 may regulate cell proliferation in p53-independent manners. Previous studies have demonstrated functional redundancy between Smad1 and Smad5 and the doses of Smad1 and Smad5 alleles are critical in embryonic development (Arnold et al., 2006; Eivers et al., 2008) . To test a possible dose effect on cell proliferation, we knocked down Smad5 and found that this had no significant effect on cell proliferation of either p53 2/2 or WT MEFs, whereas knockdown of both Smad1 and Smad5 showed similar results as Smad1 knockdown ( Figure 3C ), suggesting that Smad1 and Smad5 play different roles in MEF proliferation. There is reported evidence that Smad1 and Smad5 have distinct or even opposite functions in vivo (Dick et al., 1999; Liu et al., 2003; McReynolds et al., 2007) . Alignment of mouse Smad1 and Smad5 protein sequences reveals that the identity between these two proteins is 88%. The divergent region is the linker located between the MH1 and MH2 domains (Supplementary Figure S5) , which contains residues that are phosphorylated by various kinases, e.g. mitogen-activated protein kinases (MAPKs), glycogen synthase kinase (GSK), and Atm (Fuentealba et al., 2007; Sapkota et al., 2007; Eivers et al., 2008; Chau et al., 2012) . A few potential phosphorylation sites are not shared by Smad1 and Smad5 ( Figure 3E ), e.g. Ser181, Ser191, and Thr235. Yet, how the linker region including the phosphorylation sites determines distinct functions of Smad1 and Smad5 warrants further investigation. MEFs ( Figure 4A and B). Our previous studies have shown that overexpression of Smad1 inhibits cell transformation in p53 2/2 or WT MEFs (Chau et al., 2012) . These results suggest that Smad1 elevation has an inhibitory effect on cell transformation in p53 2/2 cells.
Similar to the cell proliferation results ( Figure 3B ), Smad5 knockdown showed little effect on cell transformation rates whereas knockdown of both Smad1 and Smad5 gave rise to similar results as Smad1 knockdown ( Figure 4A and B). These results demonstrate an inhibitory role for Smad1 in cell proliferation and transformation, a function not shared by Smad5.
Knockdown of Smad1 promotes tumor formation of p53 2/2 cells
We then tested whether Smad1 elevation in p53 2/2 MEFs has any effect on tumorigenesis. The transformed MEFs described in Figure 4A and B were transplanted into nude mice. Smad1 knockdown in p53 2/2 MEFs accelerated tumorigenesis ( Figure 4C ), which was similarly observed in WT MEFs ( Figure 4D ). Histological analysis of the tumors revealed that knockdown of Smad1 increased the cellularity of tumor (Supplementary Figure S6) . These findings suggest that Smad1 elevation in p53 2/2 cells helps to repress cell transformation and tumor formation via suppressing cell proliferation, and thus is likely to act as a compensatory mechanism for p53 deficiency, indicating that Smad1 must repress cell proliferation via p53-independent mechanisms. Although Smad5 knockdown did not significantly alter cell proliferation and transformation, it inhibited tumorigenesis of p53 2/2 cells but not WT cells. Knockdown of both Smad1 and Smad5 gave rise to results in between Smad1 knockdown and Smad5 knockdown ( Figure 4C and D) , suggesting that Smad5 plays a role opposite to Smad1 in p53 2/2 tumor growth.
Smad1 knockdown sensitizes tumors to the chemotherapeutic effects of Dox
We then asked whether elevated levels of Smad1 in tumor cells have any effect on chemotherapeutic efficacy. We took advantage of the tumor models developed in nude mice and treated them with Dox for a week and monitored the size of tumors. We started Dox treatment when the tumor sizes reached 200 mm 3 . It was found that tumors derived from p53 2/2 cells with Smad1 knockdown showed increased sensitivity to Dox treatment ( Figure 5A ). Moreover, Smad1 knockdown also increased the sensitivity to Dox treatment in tumors derived from WT cells ( Figure 5B ). We found that Smad1 could be activated by Dox in transformed MEFs, cancer cell lines, and tumors, which may regulate cell proliferation and/or death [ (Chau et al., 2012) and data not shown]. We stained the cancer samples for cell proliferation marker Ki67 and found that Smad1 knockdown tumors showed a greater reduction in the number of S phase cells than control tumors in response to Dox treatment (Supplementary Figure S7) . Similarly, transformed MEFs with Smad1 knockdown also showed a modest decrease in cell proliferation, judged by BrdU incorporation, and a significant decrease in cell survival rate in response to Dox treatment ( Figure 5C and D). These cells with Smad1 knockdown also showed a decrease in cell survival rate in response to two genotoxic drugs 5-iodotubercidin and oxaliplatin ( Figure 5E and F) (Zhang et al., 2013b) . These results suggest that Smad1 knockdown might improve chemosensitivity by inhibiting cell proliferation and survival.
We found that tumors derived from p53 2/2 cells with Smad5 knockdown showed decreased sensitivity to Dox treatment, and knockdown of both Smad1 and Smad5 showed sensitivity similar to control cells, in between Smad1 knockdown and Smad5 knockdown ( Figure 5A ), suggesting that Smad5 might also play a role opposite to Smad1 in chemosensitivity.
Smad1 knockdown sensitizes colorectal cells and cell lines to genotoxic stress-induced cell death
To confirm the role for Smad1 in chemosensitivity, we tested three colorectal tumor cell lines HCT116, Caco-2, and HT29.
Smad1 knockdown with siRNA in these cell lines resulted in a decrease in BrdU incorporation, although to modest extents, and sensitized these cells to Dox-induced cell death, to a greater extent than in MEFs ( Figure 6A-C) . Primary human rectal tumor cells with Smad1 knockdown also showed a significant decrease in cell proliferation and survival in response to Dox treatment ( Figure 6D and E). Smad1 knockdown also increased the sensitivity of primary cancer cells to anti-cancer drug oxaliplatin ( Figure 6F ). Further analysis showed that Dox-induced cell death mainly occurred by apoptosis, with a small percentage of cells undergoing necrosis in cells with Smad1 knockdown (Supplementary Figure  S8A) . It has been reported that Dox might kill cancer cells via generating reactive oxygen species (ROS). We found that pre-treating the cells with 5 mM N-Acetylcysteine (NAC), a ROS scavenger, only modestly inhibited Dox-induced cell death (Supplementary Figure S8B) , suggesting that ROS may play a minor role in Dox-induced cell death under this setting. Nevertheless, the results derived from in vivo tumor model, colorectal cancer lines, and primary rectal cancer cells all indicate that reducing Smad1 levels can increase chemosensitivity by inhibiting cell proliferation and survival, with the inhibition on survival more pronounced.
Smad1 elevation/activation increases p57Kip2 expression and Atm -Chk2 activation
We then wanted to understand how elevated Smad1 expression/ activation inhibits cell proliferation and transformation in p53-deficient cells? Our recent study indicates that CDK inhibitor p57Kip2 is a Smad1 target gene in DDR and it renders chemoresistance by suppressing cell death (Jia et al., 2014) . In consistent with the increase in Smad1 expression and activation, we found that the levels of p57Kip2 were increased at basal level and in response to Dox in p53 2/2 MEFs, which was diminished by Smad1 knockdown ( Figure 7A) . We have previously shown that p57Kip2 was upregulated in 22 rectal tumors compared with the matched paraneoplastic specimens (Jia et al., 2014) , which were the same samples used in this study ( Figure 1A and Supplementary Figure S1 ). We compared Smad1 upregulation and p57Kip2 upregulation in these tumor samples and found that there exists a significant association between these two events (Supplementary Figure S9A) . Knockdown of Smad1 in human rectal tumor cells also led to a decrease in p57Kip2 (Supplementary Figure S9B) , suggesting that p57Kip2 elevation in colorectal tumors is mediated by Smad1. Moreover, ectopic expression of Smad1 in WT MEFs led to an increase in p57Kip2, which was not further increased by Dox treatment ( Figure 7B ). In addition, Dox-induced Atm -Chk2 activation was enhanced in p53 2/2 MEFs, which could be impeded by Smad1 knockdown ( Figure 7A) , and elevated expression of Smad1 was able to potentiate Atm -Chk2 activation in response to Dox ( Figure 7B ). These results suggest that the BMP-Smad1 pathway, in addition to the Atm -p53 pathway, also plays a positive role in Atm -Chk2 activation in DDR. The increase in p57Kip2 expression and Atm-Chk2 activation may explain how elevated Smad1 suppresses cell proliferation and transformation, whereas increased expression of p57Kip2 may mediate the effects of Smad1 on chemoresistance. showed an increase in p57Kip2 expression and Atm-Chk2 activation, which was diminished by Smad1 knockdown. Primary p53 +/+ and p53
2/2
MEFs were transfected with control or Smad1 siRNA for 2 days, and were then challenged with Dox. The protein levels of Atm, Chk2, p57Kip2, Actin, Smad1, p-Atm, and p-Chk2 were analyzed by western blot. Right panels show quantitation data. n ¼ 3. *P , 0.05 vs. p53 +/+ cells under the same treatment. **P , 0.05 vs. control siRNA-transfected cells of the same genotype under the same treatment (color matched). (B) Ectopic expression of Smad1 in WT MEFs increased p57Kip2 expression and Atm -Chk2 activation. Primary WT MEFs were infected with Smad1-expressing retrovirus or empty retrovirus for 2 days, and were then challenged with Dox. The protein levels of Atm, Chk2, p57Kip2, Actin, Smad1, p-Atm, and p-Chk2 were analyzed by western blot. Right panels show quantitation data. n ¼ 3. *P , 0.05 vs. cells infected with empty vector under the same treatment. (C) A diagram showing that elevated Smad1 expression/activation inhibits cell proliferation/transformation via increasing p57Kip2 expression and Atm-Chk2 activation, and causes chemoresistance via increasing p57Kip2 expression.
Discussion
The TGFb superfamily plays critical roles in development and tissue homeostasis. The TGFb subfamily and its downstream Smad2/3 have long been known to have anti-proliferative activities. Smad2/3 can interact with p53 to induce the expression of target genes such as p21Cip1 to inhibit cell proliferation (Cordenonsi et al., 2003; Kortlever et al., 2006; Shirai et al., 2011; Samarakoon et al., 2013; Overstreet et al., 2014) . The BMP subfamily also has tumor suppressive activities, especially in colorectal tissues (Ming Kwan et al., 2004; Pangas et al., 2008; Neumann et al., 2011) , although BMPs have been reported to have pro-proliferative activity in certain cell types, which can be antagonized by TGFb (Goumans et al., 2003) . Our previous studies have shown that the BMP-Smad1 pathway is activated by Atm in response to DNA damage. Smad1 then interacts with p53 and stabilizes p53. On top of that, this study reveals that when p53 is mutated or expressed at low levels, Smad1 is upregulated, which helps to suppress cell proliferation and oncogenesis, by increasing p57Kip2 expression and enhancing Atm -Chk2 activation ( Figure 7C) . Thus, Smad1 elevation may act as a compensation for p53 mutation/loss. These findings further highlight the significance of Smad1-p53 interplay and suggest that smad1 suppresses tumorigenesis with both p53-dependent and p53-independent mechanisms.
While our previous study identified Smad1 as a DDR effector molecule that interacts with and stabilizes p53, this study suggests that Smad1 can influence Atm -Chk2 activation as well, especially in p53-deficient cells ( Figure 7C ). Smad1 knockdown compromises Atm -Chk2 activation, while elevated expression of Smad1 potentiates Atm -Chk2 activation. Atm activation mainly occurs at the double-stranded DNA breaks, yet the activation mechanism is currently unknown (Lord and Ashworth, 2012) . We found that Smad1 does not interact with Atm and is not localized to the DNA damage-induced foci (Chau et al., 2012) . It is possible that BMP -Smad1 may affect the expression of proteins that help Atm foci recruitment and/or activation. Interestingly, recent studies revealed that the TGFb-Smad2/3 pathway is also involved in DDR (Wang et al., 2013; Barcellos-Hoff and Cucinotta, 2014) . TGFb receptor activation is required for Atm activation, and Smad2 and Smad7 are localized on DNA damage-induced nuclear foci (Kirshner et al., 2006; Zhang et al., 2006; Park et al., 2015) . Yet, how BMP -Smad1 signaling regulates Atm activation and whether Smad7 mediates this effect of Smad1 await further investigation.
It has been reported that BMP-Smad1 signaling is inhibited in some human tumor types Chau et al., 2012) . However, our present study shows that Smad1 protein level is upregulated in colorectal cancer samples. Based upon the findings that p53 deficiency leads to elevated Smad1 expression in primary MEFs, NSCs, and osteoblasts, which is accompanied by elevated Smad1/5/8 activation, we conceive that during tumorigenesis, p53 defects lead to a compensatory Smad1 upregulation and momentarily activation, which helps to suppress tumor formation; late deactivation of BMP receptor due to further mutations facilitates tumor progression. Thus, our results and others reveal a dynamic change of Smad1 expression and activation in colorectal cancer, which appears to play critical roles in tumor suppression.
This study also provides evidence to support the concept that there is a division of labor between Smad1 and Smad5 in tumorigenesis. It is generally believed that Smad1, 5, and 8 have redundant functions. Here we show that only Smad1 is upregulated in the absence of p53, and only Smad1 knockdown appears to enhance cell transformation and tumor formation and sensitize tumor cells to Dox treatment. Moreover, only Smad1 is activated and upregulated in response to DNA damage (Chau et al., 2012) . Functionally, while Smad5 knockdown did not significantly affect cell proliferation and cell transformation, it seems to play a role opposite to Smad1 in tumor growth and chemosensitivity to Dox. Mechanistically, the different functions of Smad1 and Smad5 could be caused by targeting different sets of genes or by responding to different ligands, as revealed during embryonic hematopoiesis (Liu et al., 2003; McReynolds et al., 2007) .
While elevated Smad1 helps to inhibit cell proliferation and tumorigenesis in p53-deficient cells, our findings suggest that elevated Smad1 also renders chemoresistance in tumors and tumor cells. This may be explored to enhance chemosensitivity in treatment of colorectal cancer (Lee et al., 2011; Langenfeld et al., 2013) . Our present and previous studies suggest that p57Kip2 may be an important mediator of the effects of elevated Smad1 on chemoresistance ( Figure 7C) , based on the following observations. Firstly, p57Kip2 is co-elevated with Smad1 in colorectal tumor samples. Secondly, p57Kip2 is a target gene of Smad1 and is upregulated in response to chemotherapeutic drugs. Thirdly, knockdown of Smad1 or p57Kip2 enhances chemosensitivity in p53-proficient or p53-deficient tumors.
In summary, analysis of Smad1 expression in .500 patient tumor samples uncovered that Smad1 is often upregulated in colorectal cancers, which was attributable to p53 defects. Smad1 elevation appears to act as a feedback compensatory mechanism in p53 2/2 cells to help curb cell proliferation, cell transformation, and tumor formation, via increasing p57Kip2 expression and Atm -Chk2 activation. Moreover, elevated Smad1 also causes chemoresistance, which may involve p57Kip2. Thus, Smad1 might be a target to improve chemotherapeutic efficacy. Moreover, our study also reveals that Smad5 plays roles distinct from Smad1 in tumor growth and chemosensitivity. animal colonies at Bio-X Institutes, Shanghai Jiao Tong University. Mouse embryonic fibroblasts were isolated from E13.5 embryos following a standard protocol.
Materials and methods
Isolation of primary rectal tumor cells and cell cultures
A portion of rectal cancer tissue was cut into small pieces and enzymatically digested with 0.5% Trypsin -EDTA (Gibco). The dispersed tissue was filtered through a 100-mm cell strainer (BD Falcon), and the cells were washed with PBS and cultured. The primary tumor cells were cultured in DMEM/F12 (1:1), whereas MEFs, HCT116, Caco-2, and HT-29 were cultured in DMEM, which were supplemented with 10% FBS.
Smad1 knockdown
For transient Smad1 knockdown, siRNAs were used (Thermo Scientific and Santa Cruz Biotechnology, Inc.). For stable knockdown of Smad1, four shRNA hairpins expressed by a retrovirus vector (37928, 31427, 32418, and 30824, Dharmacon, Inc.) were tested. Two of them (37928 and 30824) could efficiently knock down Smad1 and were used further in this study. The experiments that involve stable Smad1 knockdown were carried out using the two shRNA hairpins with three repeats for each of them.
Immunohistochemistry and estimation of Smad1 expression
Expression of Smad1 in normal and tumor tissues from the patients was examined by immunohistochemistry using a monoclonal antibody to Smad1 (ab108994, abcam, dilution 1:200) and DAB-based staining technique (Dako ChemMate TM Envision TM Kit). The sections were counterstained with Mayer's hematoxylin (see Supplementary Materials and methods for scoring Smad1 protein levels).
BrdU labeling assay
Cell proliferation rate was determined with the BrdU assay as previously described (Jia et al., 2014) .
Trypan blue exclusion assay
Cells treated with Dox were trypsinized from culture plates, pooled with floating cells from medium, and centrifuged at 1000 g for 10 min at 48C. Trypan blue dissolved in buffered phosphate-buffered saline (pH 7.2) was added to the cell cultures to a final concentration of 0.04%. The number of live cells was counted using hemocytometer under a light microscope. The results were expressed as percentage of live cells.
Cell viability assay
Cell viability was measured with the water-soluble tetrazolium salt (WST-1) assay (Roche Diagnostics), as previously described (Jia et al., 2014) . IC 50 was calculated from the cell survival curves. When IC 50 could not be obtained from the survival curves, especially of control cells, additional experiments using higher concentrations of Dox were carried out to determine the IC 50 values.
Real-time PCR analysis
Total RNA was extracted from cells with TRIzol reagent (Invitrogen) following the manufacturer's protocol. Complementary DNAs were synthesized with 0.5 mg of total RNA using iScript cDNA Synthesis Kit (Fermentas). The detection and quantification of target mRNA were performed with real-time PCR.
Western blot analysis
Western blot analysis was carried out as previously described (Jia et al., 2014) . Anti-Smad1 (9743), Smad5 (9517), p-Smad1/5/8 (9511), p53 (2524), p-Atm (S1981) (4526S), p-Chk2 (Thr68) (2661S), Chk2 (2662), and E2F1 (3742) antibodies were purchased from Cell Signaling Technology. Anti-Actin (SC81178) antibody was purchased from Santa Cruz Biotechnology, Inc. Antibodies against Atm (GTX70103) were from Genetex. The protein bands were quantitated using the software provided by FluorChem M system (ProteinSimple) and the average of three repeated experiments was shown.
Cell transformation and tumorigenesis
Cell transformation and tumorigenesis assays were carried out as previously described (Jia et al., 2014) .
Statistical analysis
Associations between expression of Smad1 and clinicopathological variables were analyzed by non-parametric analysis, using Mann-Whitney U-test for dichotomization variables and Kruskal -Wallis test for the others. All statistical analyses were conducted using SPSS 17.0 statistical software. For other studies, statistical analysis was performed using an unpaired t-test. Significant association was defined when P , 0.05 compared with control. Pearson's correlation analysis was used to determine the correlation of the expression levels of Smad1 and p53 using SPSS 17.0 software. R ≥ 0.6 is deemed significant association.
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